The present invention pertains to a pharmaceutical composition for treating chronic obstructive pulmonary disease, as well as a method thereof.
Stem cells are multi-potent cells with a wide range of potential therapeutic applications [1]. Stem cell therapy has been a promising therapy for pulmonary diseases, including asthma, bronchopulmonary dysplasia (BPD), and chronic obstructive pulmonary disease (COPD) [2-4]. In preclinical studies, stem cells treatment has shown promising result against lung disorders [5-7]. Furthermore, clinical studies have demonstrated that the administration of stem cells to patients having advanced-stage COPD is safe and without significant adverse effects [8-11]. In stem cell-based therapies, intravenous infusion is commonly used to deliver stem cells for preclinical and clinical applications in pulmonary diseases [12-15].
U.S. Pat. No. 9,415,036 B2 discloses a pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases including an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells.
In one aspect, the present invention provides a pharmaceutical composition for treating chronic obstructive pulmonary disease. The pharmaceutical composition includes an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent.
In another aspect, the present invention provides a method for treating chronic obstructive pulmonary disease in a subject in need thereof. The method comprises the step of administering to the subject a pharmaceutical composition comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent.
According to the present invention, the pharmaceutical composition may be prepared by a method comprising: mixing the human mesenchymal stem cells with the pharmaceutically acceptable carrier or diluent, which is supplemented with an effective amount of human serum albumin.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention.
The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred.
In the drawings:
In one aspect, the present invention provides a pharmaceutical composition for treating chronic obstructive pulmonary disease (COPD). The pharmaceutical composition includes an effective amount of human mesenchymal stem cells, human serum albumin (HSA), and a pharmaceutically acceptable carrier or diluent.
In another aspect, the present invention provides a method for treating chronic obstructive pulmonary disease (COPD) in a subject in need thereof. The method comprises the step of administering to the subject a pharmaceutical composition comprising an effective amount of human mesenchymal stem cells, human serum albumin (HSA), and a pharmaceutically acceptable carrier or diluent.
The term “mesenchymal stem cells” as used herein includes cells isolated from tissues of adults, such as bone marrow, a fat cell, and a periodontal membrane, as well as cells isolated from tissues of fetus, placenta, and cord blood. In some examples of the present invention, the mesenchymal stem cells are derived from a placenta-related tissue selected from the group consisting of amniotic membrane, chorionic disk, chorionic membrane, and umbilical cord.
According to one embodiment, the pharmaceutically acceptable carrier or diluent is a normal saline.
According to the present invention, the amount of human serum albumin is effective in enhancing the efficacy of stem cell therapy for COPD, and can be determined by a person of ordinary skill in the art through routine experimentation.
According to certain embodiments of the present invention, the amount of the human serum albumin is ranging from 0.5% (w/v) to 25% (w/v), preferably 1% (w/v) to 10% (w/v), based on the volume of the pharmaceutically acceptable carrier or diluent.
As used herein, w/v means g/mL.
According to the present invention, the pharmaceutical composition may be prepared by a process comprising: mixing the human mesenchymal stem cells with the pharmaceutically acceptable carrier or diluent, which is supplemented with the human serum albumin.
Said process may further comprise incubating the human mesenchymal stem cells, as a suspension culture, in the pharmaceutically acceptable carrier or diluent, for a period of time to transform the condition of the human mesenchymal stem cells to one which is more effective in treating COPD in a stem cell-based therapy. A person of ordinary skill in the art may determine, through routine experimentation, an adequate period of time for incubating the human mesenchymal stem cells, such that the pharmaceutical composition is more effective in treating chronic obstructive pulmonary disease as compared to a pharmaceutical composition which is not “activated” by said process before use. In other words, the method for treating chronic obstructive pulmonary disease of the present invention may further comprise the preliminary steps of: mixing the human mesenchymal stem cells with the pharmaceutically acceptable carrier or diluent, which is supplemented with the human serum albumin, and incubating the pharmaceutical composition to transform the condition of the human mesenchymal stem cells to one which is more effective in treating COPD in a stem cell-based therapy.
However, since a pharmaceutical composition comprising stem cells is generally administered to a subject in need thereof gradually over a relatively long period of time, the pharmaceutical composition of the present invention may also be used shortly after the human mesenchymal stem cells are mixed with the pharmaceutically acceptable carrier or diluent supplemented with human serum albumin.
The present invention is further illustrated by the following examples, which are provided for the purpose of demonstration rather than limitation.
Full-term placentas were collected after obtaining written informed consent from donors. MSCs were derived from amniotic membrane (AM), chorionic disk (CD), chorionic membrane (CM), and umbilical cord (UC). Placenta-derived mesenchymal stem cells were cultured, expanded and maintained in α-MEM with FBS and basic FGF at 37° C., saturating humidity and 5% CO2, and were sub-cultured when cells reached 80% confluence. The cells are stored under low temperature conditions before use.
1×107 mesenchymal stem cells (prepared as described in Example 1) were mixed with normal saline supplemented with different amounts (0, 1% (w/v), 2.5% (w/v), 5% (w/v), 7.5% (w/v), and 10% (w/v), based on the volume of normal saline) of human serum albumin (HAS), and incubated for 4 hours. Cell viability and cell number were measured by a cell counter (NucleoCounter® NC-250, ChemoMetec). The results are shown in
1×107 mesenchymal stem cells (prepared as described in Example 1) were mixed with normal saline supplemented with different amounts (0, 1% (w/v), 2.5% (w/v), 5% (w/v), 7.5% (w/v), and 10% (w/v), based on the volume of normal saline) of HSA, and incubated for 4 hours. Human normal lung fibroblasts MRC-5, were treated with 8% cigarette smoke extract (CSE) for 24 hours, and then co-cultured with or without the mesenchymal stem cells for 48 hours. The mesenchymal stem cells were co-cultured with the CSE-damaged MRC-5 cells by using 24-well insert plates with 0.4 μm membrane pore sizes. Viability of the MRC-5 cells was analyzed by CCK-8 assay. The results are shown in
It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the appended claims.